Project Grant R01NS138137
Award Date
5/6/25
Completion Date
3/31/30
Dollars Obligated
$420K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $687,279 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research to dissect the immune responses and cellular composition within the tumor microenvironment of glioblastoma (GBM). The project aims to leverage spatial transcriptomics and proteomics analysis of archival human GBM samples and mouse models to uncover the effects...
This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to improve immunogene therapy for the treatment of glioblastoma, a highly fatal type of brain cancer. The $633,656 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, will support preclinical research to investigate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), provides USD 627,061 to develop innovative oncolytic immunotherapies for the treatment of glioblastoma (GBM), a fatal form of brain cancer. The key objectives are to: Determine if combining MGH's genetically-engineered oncolytic herpes simplex virus (oHSV) expressing IL-12 with inhibitors of...
This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the development of a murine glioblastoma model to evaluate the use of oncolytic herpes simplex virus (HSV) therapy for grade IV brain tumors. The total funding amount is $794,967.00, with a project period from July 9, 2024 to June 30, 2026. The goal is to create an...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $417,858 to Brigham & Women's Hospital Inc. to develop novel cellular therapies for the treatment of glioblastoma (GBM), a highly malignant brain cancer. The project aims to engineer mesenchymal stem cells (MSCs) to produce bi-specific T cell engager (BiTE) molecules that can redirect T cells to target multiple antigens overexpressed in GBM, including EGFR, EGFRvIII, and...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $230,580 to Brigham & Women's Hospital Inc. to conduct research focused on understanding the mechanisms underlying brain-immune interactions at the blood-brain barrier. The overarching goal is to generate novel targets for immunotherapy in neuroinflammatory...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is designed to validate a novel treatment for glioblastoma, an aggressive and deadly form of brain cancer, using oncolytic Zika virus. The $500,000 award will fund IND-enabling experiments to advance this potential new therapy into clinical trials. The awardee, Up...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products and services to be delivered under this award include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $449,203 to support research aimed at investigating the interaction between glioblastoma (GBM), the most aggressive form of brain cancer, and the subventricular zone (SVZ) neurogenic niche in the lateral ventricles. The research, led by Mayo Clinic Jacksonville, a nonprofit...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $574,427 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of Pittsburgh to investigate the role of amino acid metabolism in regulating the growth and immune interactions of glioblastoma, an aggressive form of brain cancer. The research aims to uncover the molecular and cellular mechanisms by which selective amino acid catabolism in glioblastoma...